INHANCE Stemless Reverse Shoulder IDE
Randomisert, prospektiv, multisenterstudie av INHANCE Stemless Total Reverse Shoulder System
2:1 Randomized, Controlled, Multi-Center, Prospective, Pre-Market Study of the INHANCE Stemless Reverse Cementless Total Shoulder.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
There is one primary effectiveness endpoint and there are three primary safety endpoints:
-
Primary effectiveness endpoint - Adjusted Constant-Murley Change from Baseline (ACM CFB) at 2 years post-operative
-
Primary safety endpoint(s):
- No revision, removal, reoperation, supplemental fixation, or other intervention for any system component
- No humeral or glenoid radiolucent line >2 mm is present in 50% or more zones at 2 years
- No conclusive evidence of migration and tilt (>5mm migration and >10° tilt) of the humeral or glenoid component at 2 years
The study will be successful if the primary effectiveness endpoint non-inferiority analysis is successfully demonstrated, and no significant difference is seen on any of the 3 primary safety endpoints.
Studietype
Studietype
Registrering (Faktiske)
Registrering
Fase
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Florida
-
Atlantis, Florida, Forente stater, 33462
- Orthopedic Center of Palm Beach County
-
-
Massachusetts
-
Waltham, Massachusetts, Forente stater, 02451
- Boston Bone & Joint Institute BBJI Formerly BSSC
-
-
Michigan
-
Grand Rapids, Michigan, Forente stater, 49503
- Trinity Health Grand Rapids
-
-
Missouri
-
Columbia, Missouri, Forente stater, 65201
- Missouri Orthopaedic Institute (MOI)
-
-
North Carolina
-
Charlotte, North Carolina, Forente stater, 28207
- OrthoCarolina Research Institute Charlotte
-
Raleigh, North Carolina, Forente stater, 27609
- Duke Orthopaedics of Raleigh
-
-
Ohio
-
Akron, Ohio, Forente stater, 44333
- Crystal Clinic Orthopaedic Center
-
Cincinnati, Ohio, Forente stater, 45219
- Lindner Research Center
-
Cleveland, Ohio, Forente stater, 44195
- The Cleveland Clinic Foundation
-
-
Oregon
-
Eugene, Oregon, Forente stater, 97401
- Slocum Center for Orthopaedics and Sports Medicine
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, Forente stater, 18015
- St. Luke's University Health Network
-
Philadelphia, Pennsylvania, Forente stater, 19107
- Rothman Orthopaedics Institute
-
-
Tennessee
-
Columbia, Tennessee, Forente stater, 38401
- MTBJ a division of Tennessee Orthaepedic Alliance
-
-
Utah
-
Salt Lake City, Utah, Forente stater, 84108
- University of Utah
-
-
Virginia
-
Fredericksburg, Virginia, Forente stater, 22408
- Mary Washington Orthopedics in affiliation with FOA
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Individuals requiring reverse total shoulder replacement for a severely painful, disabling, arthritic joint (i.e. osteoarthritis, post-traumatic arthritis and rotator cuff arthropathy).
- Individuals who are anatomically and structurally suited to receive the implants and have a functional deltoid muscle.
- Individuals who are able to read and comprehend the informed patient consent document and are willing and able to provide informed patient consent for participation in the study and have authorized the transfer of their information to DePuy Synthes.
- Individuals who are willing and able to return for follow-up as specified by the study protocol.
- Individuals who are a minimum age of 22 years at the time of consent.
- Individuals who are willing and able to complete the Patient Reported Outcome Measure questionnaires (PROMs) as specified by the study protocol.
Exclusion Criteria:
- BMI > 40 kg/m2
- Individuals have active, uncontrolled local infection or systemic infection.
- Patients who have not reached skeletal maturity, regardless of age.
- Either preoperatively or intraoperatively and per standard of care medical assessment, bone stock in the proximal humerus or glenoid fossa is determined to be inadequate for supporting the INHANCE humeral stemless components (NOTE: exclusion applies to both arms of the study, i.e., bone stock to be evaluated independent of randomized treatment assignment).
- Intraoperatively and per treating physician's assessment of bone quality, bone is determined to be too soft or porous to support the implant or that is too hard or brittle to allow for proper bone preparation and fixation, i.e. osteoporosis or sclerotic bone, or tumor(s) of the supporting bone structure, where there could be considerable migration of the prosthesis and/or a chance of fracture of the humerus or glenoid.
- Fractures of the proximal humerus that could compromise the fixation of the INHANCE reverse humeral stemless components.
- Patients who have undergone previous treatment on the study shoulder that may compromise fixation of the INHANCE reverse humeral stemless component.
- Revision of a failed hemi, total or reverse shoulder arthroplasty.
- Patient is receiving, or is scheduled to receive, treatment that the Investigator considers could affect bone quality, such as chemotherapy or high dose corticosteroids.
- Individuals who are bedridden per the Investigator's determination.
- Individuals that have participated in a clinical investigation with an investigational product (drug or device) in the last three months.
- Individuals currently involved in any personal injury litigation, medical-legal or worker's compensation claims.
- Individuals, in the opinion of the Investigator, who are drug or alcohol abusers or have psychological disorders that could affect their ability to complete patient reported questionnaires or be compliant with follow-up requirements.
- Patients with a known medical condition that the Investigator believes would impact the study outcomes (including, but not limited to osteomyelitis, Paget's disease, neuropathies such as Charcot's disease, metastatic or neoplastic disorders).
- Patient has a medical condition with less than 2 years life expectancy.
- Patients who are known to be pregnant or breastfeeding.
- Known polyethylene and/or metal sensitivity or allergy.
- Contralateral side has been enrolled in the study or has received a total shoulder operation within the last 6 months
- Otherwise determined by the investigator to be medically unsuitable for participation in this study
- Patient is a member of a vulnerable population (i.e., incarcerated individuals - those incarcerated for at least one month and considered to be an inmate)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: INHANCE Stemless Reverse
INHANCE(TM) Stemless Reverse Total Shoulder |
Uncemented Reverse Total Shoulder |
|
Aktiv komparator: INHANCE Stemmed Reverse
INHANCE(TM) Stemmed Reverse Total Shoulder |
Uncemented Reverse Total Shoulder |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Constant Murley Score (CMS)
Tidsramme: Pre-op, 2 years
|
Primary effectiveness endpoint - Adjusted Constant-Murley Change from Baseline (ACM CFB) at 2 years post-operative. The CMS is a 100 point scale, the higher the score, the higher the quality of the function. ACM will be obtained by dividing the raw score by the relative score. |
Pre-op, 2 years
|
|
Removal of any system component
Tidsramme: 2 year
|
No removal of any system component |
2 year
|
|
Revision of any system component
Tidsramme: 2 year
|
No revision of any system component |
2 year
|
|
Reoperation of any system component
Tidsramme: 2 year
|
No reoperation of any system component |
2 year
|
|
Supplemental Fixation of any system component
Tidsramme: 2 year
|
No supplemental fixation of any system component |
2 year
|
|
Radiolucent Lines (Humeral & Glenoid)
Tidsramme: 2 year
|
No humeral or glenoid radiolucent line greater than 2mm is present in 50% or more zones |
2 year
|
|
Migration and Tilt (Humeral & Glenoid)
Tidsramme: 2 year
|
No conclusive evidence of migration and tilt (greater than 5mm migration and greater than 10 degrees tilt) of the humeral or glenoid component |
2 year
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Constant Murley Score (CMS)
Tidsramme: Pre-op, 3-month, 6-month, 1 year, 2 year
|
Adjusted Constant-Murley Score at baseline and 3- and 6-months and 1- and 2-years post-operative. The CMS is a 100 point scale, the higher the score, the higher the quality of the function. ACM will be obtained by dividing the raw score by the relative score. |
Pre-op, 3-month, 6-month, 1 year, 2 year
|
|
EQ-5D-5L and EQ-VAS
Tidsramme: Pre-op, 3-month, 6-month, 1 year, 2 year
|
EQ-5D-5L Scores by dimension and EQ-VAS, at baseline and 3- and 6-months and 1- and 2-years post-operative. The value score generally ranges from less than 0 to 1, with higher scores indicating higher health utility. The EQ VAS records the subject's self-rated health from 0 (worst) to 100 (best). |
Pre-op, 3-month, 6-month, 1 year, 2 year
|
|
Simple Shoulder Test
Tidsramme: Pre-op, 3-month, 6-month, 1 year, 2 year
|
Simple Shoulder Test (SST) Scores at baseline and 3- and 6-months and 1- and 2-years post-operative. Scores range from 0 (worst) to 12 (best). |
Pre-op, 3-month, 6-month, 1 year, 2 year
|
|
Single Assessment Numeric Evaluation (SANE) Score
Tidsramme: Pre-op, 3-month, 6-month, 1 year, 2 year
|
Single Assessment Numeric Evaluation (SANE) Scores at baseline and 3- and 6-months and 1- and 2-years post-operative. The scale is 0 to 100 with 100 being "normal". |
Pre-op, 3-month, 6-month, 1 year, 2 year
|
|
Survivorship
Tidsramme: 2 year
|
Overall survivorship of the INHANCE Shoulder System at 2 years post-operative, where the system is deemed to be surviving if no components (humeral stem or stemless component, glenosphere, baseplate, liner, etc.) have been removed for any reason, will be presented using the Kaplan-Meier method. |
2 year
|
|
Complications
Tidsramme: 2 year
|
The type and frequency of all reportable adverse events (AEs) and device deficiencies in this study will be summarized, with distinction of serious AEs, device and procedure related AEs |
2 year
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Constant Murley Score (CMS)
Tidsramme: Pre-op, 3-month, 6-month, 1 year
|
Change from baseline adjusted Constant-Murley Score at 3- and 6-months and 1- year post-operative. The CMS is a 100 point scale, the higher the score, the higher the quality of the function. ACM will be obtained by dividing the raw score by the relative score. |
Pre-op, 3-month, 6-month, 1 year
|
|
EQ-5D-5L and EQ-VAS
Tidsramme: Pre-op, 3-month, 6-month, 1 year, 2 year
|
Change from baseline EQ-5D-5L Value Score and EQ-VAS, at 3- and 6-months and 1- and 2-years post-operative. The value score generally ranges from less than 0 to 1, with higher scores indicating higher health utility. The EQ VAS records the subject's self-rated health from 0 (worst) to 100 (best). |
Pre-op, 3-month, 6-month, 1 year, 2 year
|
|
Simple Shoulder Test
Tidsramme: Pre-op, 3-month, 6-month, 1 year, 2 year
|
Change from baseline SST Scores at 3- and 6-months and 1- and 2-years post-operative. Scores range from 0 (worst) to 12 (best). |
Pre-op, 3-month, 6-month, 1 year, 2 year
|
|
Single Assessment Numeric Evaluation (SANE) Score
Tidsramme: Pre-op, 3-month, 6-month, 1 year, 2 year
|
Change from baseline SANE Scores at 3- and 6-months and 1- and 2-years post-operative. The scale is 0 to 100 with 100 being "normal". |
Pre-op, 3-month, 6-month, 1 year, 2 year
|
|
Range of Motion
Tidsramme: Pre-op, 3-month, 6-month, 1 year, 2 year
|
Change from baseline range of motion at 3- and 6-months and 1- and 2-years post-operative |
Pre-op, 3-month, 6-month, 1 year, 2 year
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Andre studie-ID-numre
Andre studie-ID-numre
- DSM202108
- DSM202108 (Annen identifikator: DePuy Orthopaedics)
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .